Journal article
Major Bleeding After Paracentesis Associated With Apixaban Use: Two Case Reports
Hospital pharmacy (Philadelphia), Vol.58(1), pp.34-37
07/28/2022
DOI: 10.1177/00185787221111741
PMCID: PMC9837325
PMID: 36644747
Abstract
We report 2 patients with compensated cirrhosis and moderate renal impairment who experienced severe bleeding complications from paracentesis during concurrent therapy with apixaban. While paracentesis has traditionally been considered a low bleeding-risk procedure and safe to perform without interruption of therapeutic anticoagulation, the increased concentrations observed in patients with impaired liver function may place these patients at unexpectedly high bleeding risk. Further investigation into the safety of paracentesis in patients with cirrhosis on apixaban may be warranted, as well as additional understanding of the clinical safety of this drug in Child-Pugh B cirrhosis.
Details
- Title: Subtitle
- Major Bleeding After Paracentesis Associated With Apixaban Use: Two Case Reports
- Creators
- Ethan Kuperman - Roy J. and Lucille A. Carver College of MedicineRyan A. Hobbs - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Hospital pharmacy (Philadelphia), Vol.58(1), pp.34-37
- Publisher
- Sage
- DOI
- 10.1177/00185787221111741
- PMID
- 36644747
- PMCID
- PMC9837325
- ISSN
- 0018-5787
- eISSN
- 1945-1253
- Number of pages
- 4
- Language
- English
- Date published
- 07/28/2022
- Academic Unit
- General Internal Medicine; Internal Medicine
- Record Identifier
- 9984359689402771
Metrics
8 Record Views